JP2011521974A5 - - Google Patents

Download PDF

Info

Publication number
JP2011521974A5
JP2011521974A5 JP2011511876A JP2011511876A JP2011521974A5 JP 2011521974 A5 JP2011521974 A5 JP 2011521974A5 JP 2011511876 A JP2011511876 A JP 2011511876A JP 2011511876 A JP2011511876 A JP 2011511876A JP 2011521974 A5 JP2011521974 A5 JP 2011521974A5
Authority
JP
Japan
Prior art keywords
therapeutic agent
amorphous form
drug delivery
delivery device
glass transition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011511876A
Other languages
English (en)
Japanese (ja)
Other versions
JP5695562B2 (ja
JP2011521974A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/045739 external-priority patent/WO2009158120A2/en
Publication of JP2011521974A publication Critical patent/JP2011521974A/ja
Publication of JP2011521974A5 publication Critical patent/JP2011521974A5/ja
Application granted granted Critical
Publication of JP5695562B2 publication Critical patent/JP5695562B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011511876A 2008-05-30 2009-05-29 安定化された経皮薬物送達システム Active JP5695562B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5745508P 2008-05-30 2008-05-30
US61/057,455 2008-05-30
PCT/US2009/045739 WO2009158120A2 (en) 2008-05-30 2009-05-29 Stabilized transdermal drug delivery system

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014232586A Division JP2015083569A (ja) 2008-05-30 2014-11-17 安定化された経皮薬物送達システム

Publications (3)

Publication Number Publication Date
JP2011521974A JP2011521974A (ja) 2011-07-28
JP2011521974A5 true JP2011521974A5 (https=) 2015-01-15
JP5695562B2 JP5695562B2 (ja) 2015-04-08

Family

ID=41380695

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011511876A Active JP5695562B2 (ja) 2008-05-30 2009-05-29 安定化された経皮薬物送達システム
JP2014232586A Pending JP2015083569A (ja) 2008-05-30 2014-11-17 安定化された経皮薬物送達システム

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014232586A Pending JP2015083569A (ja) 2008-05-30 2014-11-17 安定化された経皮薬物送達システム

Country Status (11)

Country Link
US (2) US20110182949A1 (https=)
EP (1) EP2299989B1 (https=)
JP (2) JP5695562B2 (https=)
KR (1) KR101590209B1 (https=)
CN (1) CN102099020B (https=)
AU (2) AU2009262871B2 (https=)
BR (1) BRPI0913214B1 (https=)
CA (1) CA2726136C (https=)
MX (1) MX2010012989A (https=)
NZ (1) NZ589542A (https=)
WO (1) WO2009158120A2 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2726136C (en) * 2008-05-30 2016-11-01 Mylan Laboratories, Inc. Stabilized transdermal drug delivery system
KR101325104B1 (ko) * 2009-09-16 2013-11-07 주식회사 삼양바이오팜 경피 투여 제형 및 그 제조 방법
LT3257504T (lt) 2009-12-22 2024-08-26 UCB Biopharma SRL Polivinilpirolidonas, skirtas nekristalinės formos kietos rotigotino dispersijos stabilizavimui
CN104582693A (zh) * 2012-08-15 2015-04-29 道康宁公司 多层药物递送系统
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀(Rotigotine)之多天式貼片
JP2016135744A (ja) * 2013-05-08 2016-07-28 株式会社 ケイ・エム トランスダーム 貼付剤
JP6726096B2 (ja) 2013-07-03 2020-07-22 エルテーエス ローマン テラピー−システメ アーゲー 電子部品を有する経皮治療システム
WO2015025767A1 (ja) * 2013-08-21 2015-02-26 久光製薬株式会社 貼付剤
CN115444659A (zh) * 2014-01-22 2022-12-09 4P治疗公司 滥用和误用制止透皮系统
US11752110B2 (en) * 2014-05-20 2023-09-12 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator
CN106456566B (zh) 2014-05-20 2020-06-16 Lts勒曼治疗系统股份公司 含罗替戈汀的经皮递送系统
CA2948219C (en) 2014-05-20 2023-04-04 Lts Lohmann Therapie-Systeme Ag Method for adjusting the release of active agent in a transdermal delivery system
WO2016049266A1 (en) * 2014-09-24 2016-03-31 Pain Therapeutics, Inc. 4:3 naltrexone: 5-methyl-2-furaldehyde cocrystal
US10010543B1 (en) 2014-12-23 2018-07-03 Barr Laboratories, Inc. Transdermal dosage form
US9650338B1 (en) 2016-07-29 2017-05-16 VDM Biochemicals, Inc. Opioid antagonist compounds and methods of making and using
EP3558276B1 (en) 2016-12-20 2024-11-06 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
CN115813888A (zh) 2016-12-20 2023-03-21 罗曼治疗系统股份公司 包含阿塞那平的透皮治疗系统
KR102241892B1 (ko) 2017-01-25 2021-04-20 한국전자기술연구원 백스캐터 통신을 위한 데이터 부호화 방법 및 이를 위한 장치
EP3395336A1 (en) 2017-04-28 2018-10-31 Nitto Denko Corporation Transdermal absorption preparation
WO2019002204A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
AU2019291060B2 (en) 2018-06-20 2024-09-05 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US20220117934A1 (en) * 2019-02-15 2022-04-21 Hisamitsu Pharmaceutical Co., Inc. Rotigotine stabilization method
US20220160697A1 (en) 2019-03-19 2022-05-26 Nobelpharma Co., Ltd. Pharmaceutical composition having excellent drug absorption into the living body and excellent chemical stability
WO2020243506A1 (en) * 2019-05-31 2020-12-03 Kindeva Drug Delivery Removable film-forming gel compositions featuring adhesion promoters
ES2966170T3 (es) 2020-01-24 2024-04-18 Luye Pharma Switzerland Ag Sistema terapéutico transdérmico que comprende rotigotina y al menos un adhesivo de silicona no resistente a las aminas
TW202228688A (zh) * 2020-08-31 2022-08-01 日商耐貝醫藥股份有限公司 用於神經退化性疾病之症狀緩解或治療之貼附劑
CN112891324A (zh) * 2021-01-19 2021-06-04 北京亚宝生物药业有限公司 一种透皮贴剂
KR102363479B1 (ko) * 2021-03-12 2022-02-15 환인제약 주식회사 로티고틴 함유 경피 흡수 제제
US20220395468A1 (en) * 2021-06-06 2022-12-15 Starton Therapeutics, Inc. Transdermal Drug Delivery Systems for Administration of a Therapeutically Effective Amount of Lenalidomide and Other Immunomodulatory Agents
CN116270575A (zh) * 2021-08-16 2023-06-23 乐明药业(苏州)有限公司 一种含有氟比洛芬的药物组合物与贴剂
CN120417892A (zh) * 2022-12-26 2025-08-01 丸仁制药株式会社 透皮吸收制剂及其制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2920500A1 (de) * 1979-05-21 1980-11-27 Boehringer Sohn Ingelheim Pharmazeutische zubereitung in form eines polyacrylatfilmes
DE3204551A1 (de) * 1982-02-10 1983-08-18 Boehringer Ingelheim KG, 6507 Ingelheim Verfahren zur herstellung einer pharmazeutischen zubereitung in form eines polyacrylat-films
JPS60169414A (ja) * 1984-02-14 1985-09-02 Taisho Pharmaceut Co Ltd 経皮吸収剤
US4880633A (en) * 1986-03-12 1989-11-14 Merck & Co., Inc. Transdermal drug delivery system
US4797284A (en) * 1986-03-12 1989-01-10 Merck & Co., Inc. Transdermal drug delivery system
US4832953A (en) * 1987-08-13 1989-05-23 Alza Corporation Method for preventing the formation of a crystalline hydrate in a dispersion of a liquid in a monaqueous matrix
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
GB9021674D0 (en) * 1990-10-05 1990-11-21 Ethical Pharma Ltd Transdermal device
US5164190A (en) * 1990-12-11 1992-11-17 Theratech, Inc. Subsaturated transdermal drug delivery device exhibiting enhanced drug flux
IT1253265B (it) * 1991-11-25 1995-07-14 Rotta Research Lab Preparato a matrice copolimerica adesiva a base acrilica per il rilascio transdermico dell'estradiolo.
US5494680A (en) * 1993-12-08 1996-02-27 Minnesota Mining And Manufacturing Company Transdermal delivery device
CA2198390C (en) 1994-09-14 2009-08-11 James E. Garbe Matrix for transdermal drug delivery
US5662928A (en) * 1995-04-21 1997-09-02 Ciba-Geigy Corporation Method for the prevention or removal of crystalline scopolamine in a non-aqueous matrix of a transdermal system
KR970009795A (ko) * 1995-08-30 1997-03-27 이웅열 경피투여용 첩부제 조성물
US5906830A (en) * 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
US6238700B1 (en) * 1995-12-01 2001-05-29 Alza Corporation Method for preventing crystal formation in a dispersion of a liquid in a matrix
AU1120097A (en) * 1995-12-01 1997-06-27 Alza Corporation Improved method for preventing crystal formation in a dispersion of a liquid in a matrix
DE19548332A1 (de) * 1995-12-22 1997-07-10 Rotta Res Bv Hormonpflaster
US6623763B2 (en) * 1996-01-08 2003-09-23 Lts Lohmann Therape-System Ag Pharmaceutical preparation adhering to the skin, in particular a transdermal therapeutic system for the release of 17-β-estradiol to the human organism
US5869089A (en) * 1996-03-21 1999-02-09 China-America Technology Corp. (Ctc) Manufacturing method of programmable transdermal therapeutic system
DE19629468A1 (de) 1996-07-11 1998-01-15 Schering Ag Transdermale therapeutische Systeme
US20040018241A1 (en) * 1997-09-26 2004-01-29 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
DE19906152B4 (de) * 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
DE10060550C1 (de) * 2000-12-06 2002-04-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten
US8496960B2 (en) * 2001-10-23 2013-07-30 Purdue Pharma L.P. Terazosin transdermal device and methods
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
WO2005123046A1 (en) * 2004-06-15 2005-12-29 Amorepacific Corporation Novel transdermal preparation and its producing method
DE102004062182B4 (de) 2004-12-20 2007-06-06 Bayer Schering Pharma Ag Transdermales Pflaster mit Progesteron A-Spezifische Liganden (PRASL) als Wirkstoff
US20060188558A1 (en) * 2005-02-18 2006-08-24 Mylan Technologies, Inc. Transdermal systems having control delivery system
JP5285279B2 (ja) * 2005-12-28 2013-09-11 久光製薬株式会社 経皮吸収型製剤
US20080226698A1 (en) 2007-03-16 2008-09-18 Mylan Technologies, Inc. Amorphous drug transdermal systems, manufacturing methods, and stabilization
EP3053440B1 (en) * 2007-04-11 2020-08-12 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
CA2726136C (en) * 2008-05-30 2016-11-01 Mylan Laboratories, Inc. Stabilized transdermal drug delivery system
CA2824639A1 (en) 2011-02-17 2012-08-23 Ashish Chatterji A process for controlled crystallization of an active pharmaceutical ingredient from supercooled liquid state by hot melt extrusion

Similar Documents

Publication Publication Date Title
JP2011521974A5 (https=)
JP4883220B2 (ja) ロチゴチン含有組成物及びその使用並びにこの組成物を含む経皮貼付剤
CN1731995B (zh) 用于经皮给药d2促进素碱的器具
CN104144684B (zh) 含有多奈哌齐的经皮吸收制剂及其制备方法
JP5695562B2 (ja) 安定化された経皮薬物送達システム
CN102946873B (zh) 经皮吸收制剂
JP6335790B2 (ja) 自発的に結晶化する傾向が低い経皮治療システム
JP2016504368A5 (https=)
CN106659702A (zh) 透皮递送体系
CN104981237B (zh) 用于低熔点活性剂的经皮剂型
JP2010510260A5 (https=)
JP5665116B2 (ja) 貼付剤および貼付製剤
JP2017515869A5 (https=)
JP6948326B2 (ja) テープ材用支持フィルム、テープ材、およびテープ材用支持フィルムの製造方法
EP2570122B1 (en) Composition for Enhancing Transdermal Absorption of A Drug and Patch Preparation
CN104661657B (zh) 贴附剂或贴附制剂用的支承体以及使用该支承体的贴附剂和贴附制剂
CN104548104A (zh) 包载雌激素的三维网状立体构型的透皮制剂及其制备方法
CN104666279A (zh) 载药的三维网状立体构型的透皮给药制剂及其制备方法
JP2018537451A5 (https=)
CN103338788A (zh) 贴剂
JP5956660B2 (ja) 塩基性反応酸化物を含む制御された活性物質流動を有する経皮治療システム
CN112891324A (zh) 一种透皮贴剂
CN103313710A (zh) 贴剂
CN112826809B (zh) 一种稳定的妥洛特罗经皮吸收制剂
JP2011074035A (ja) 貼付剤